The Effects of Luo-Bu-Fu-Ke-Bi-RI Pill

To investigate the effect of LBFKBRP on climacteric syndrome in women and explore its therapeutic mechanism.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Climacteric Syndrome

Age range

41 year–60 year

Sex eligibility

Female

Study type

Observational

Primary location

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Clinical diagnosis of climacteric syndrome

Treatment and study plan

Luo-Bu-Fu-Ke-Bi-RI Pill

Drug

10 pills twice daily

Tibolone

Drug

2.5 mg once daily

Primary outcomes

Sex hormone

Time frame: 3 month

Sponsors and collaborators

Lead sponsor

Guoqing Zhou

Other

Registry information

Important dates

Study start: 2017
Primary completion: 2020
Study completion: 2021
First posted: May 6, 2023
Registry last updated: Aug 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed